Binge eating disorder

Nature Reviews Disease Primers, Journal Year: 2022, Volume and Issue: 8(1)

Published: March 17, 2022

Language: Английский

---

The American Psychiatric Association Practice Guideline for the Treatment of Patients With Eating Disorders

American Journal of Psychiatry, Journal Year: 2023, Volume and Issue: 180(2), P. 167 - 171

Published: Feb. 1, 2023

Language: Английский

---

Epidemiology of binge eating disorder: prevalence, course, comorbidity, and risk factors

Current Opinion in Psychiatry, Journal Year: 2021, Volume and Issue: 34(6), P. 525 - 531

Published: Sept. 7, 2021

Binge eating disorder (BED) is a new diagnosis in the Fifth Edition of Diagnostic and Statistic Manual Mental Disorders (DSM-5) Eleventh Revision International Classification Diseases (ICD-11).DSM-5 BED currently estimated to affect 1.5% women 0.3% men worldwide; lifetime DSM-5 reported by 0.6-1.8% 0.3-0.7% men. In adolescence, even more prevalent, but often transient. Many adults with report longstanding symptoms; less than half are recognized healthcare. Commonly co-occurring conditions include obesity, type 2 diabetes, hypertension. nationally representative US-based study, up 23% individuals had attempted suicide, virtually all (94%) mental health symptoms: 70% mood disorders, 68% substance use 59% anxiety 49% borderline personality disorder, 32% posttraumatic stress disorder. Data on mortality scarce, standardized ratio be 1.5-1.8. Various minority statuses, deprivation, violence, trauma, major illness may increase risk BED.BED invisible overlooked, perhaps due societal biases. For this reason, prevention, detection, management closely linked social justice equity.

Language: Английский

---

Epidemiology of eating disorders: population, prevalence, disease burden and quality of life informing public policy in Australia—a rapid review

Journal of Eating Disorders, Journal Year: 2023, Volume and Issue: 11(1)

Published: Feb. 15, 2023

Understanding of the epidemiology and health burden eating disorders has progressed significantly in last 2 decades. It was considered one seven key areas to inform Australian Government commissioned National Eating Disorder Research Translation Strategy 2021-2031, as emerging research had highlighted a rise disorder prevalence worsening burden-of-illness. The aim this review better understand global impact policy decision-making.Using systematic Rapid Review methodology, ScienceDirect, PubMed Medline (Ovid) were searched for peer-reviewed studies published between 2009 2021. Clear inclusion criteria developed consultation with experts field. Purposive sampling literature conducted, which predominately focused on higher-level evidence (meta-analyses, reviews, large epidemiological studies), synthesised, narratively analysed.135 deemed eligible (N = 1324). Prevalence estimates varied. Global Lifetime any ranged from 0.74 2.2% males, 2.58-8.4% females. 3-month point-prevalence broadly defined around 16% appeared more prevalent young people adolescents, particularly females (in Australia: ~ 22.2%; disordered 25.7%). Limited found sex, sexuality gender diverse (LGBTQI +) individuals, who six-fold increase compared general male population, increased illness impact. Similarly, limited First Australian's (Aboriginal Torres Strait Islander) suggests rates similar non-Indigenous Australians. No identified specifically assessing culturally linguistically populations. disease 43.4 age-standardised disability-adjusted-life-years per 100,000; increasing by 9.4% 2007 2017. total economic cost estimated at $84 billion years-of-life lost due disability death, annual earnings $1.646 billion."There is no doubt that are rise, at-risk understudied Much came female-only samples, Western, high-income countries readily have access specialised services. Future should examine representative samples. There an urgent need refined methods these complex illnesses over time, guide development-of-care.Our understanding improved past 20-years. highlights increasing. To development 2021–2031 aimed change decision-making.Three scholarly databases systematically related Searches 135 met our criteria. Estimates lifetime varied 2.58 8.4% women girls. Findings indicated women, while individuals six-times likely population. little moderate high peoples, Australia’s spending or death. rise. include populations estimate accuracy improve care all.

Language: Английский

---

MDMA-assisted therapy significantly reduces eating disorder symptoms in a randomized placebo-controlled trial of adults with severe PTSD

Journal of Psychiatric Research, Journal Year: 2022, Volume and Issue: 149, P. 128 - 135

Published: March 5, 2022

Eating disorders (EDs) and posttraumatic stress disorder (PTSD) are highly comorbid, yet there no proven integrative treatment modalities for ED-PTSD. In clinical trials, MDMA-assisted therapy (MDMA-AT) has shown marked success in the of PTSD may be promising Ninety individuals with severe received a double-blind, placebo-controlled pivotal trial MDMA-AT. addition to primary (Clinician-Administered Scale) secondary (Sheehan Disability outcome measures, Attitudes Test 26 (EAT-26) was administered pre-specified exploratory purposes at baseline study termination. The sample consisted 58 females (placebo = 31, MDMA 27) 31 males 12, 19) (n 89). Seven participants discontinued prior At baseline, 13 (15%) 89 had total EAT-26 scores range (≥20), 28 (31.5%) high-risk (≥11) despite absence active purging or low weight. completers 82), significant reduction group following MDMA-AT versus placebo (p .03). There were also reductions women high ≥11 ≥ 20 .0012 p .0478, respectively). ED psychopathology is common even EDs significantly reduced symptoms compared among PTSD. ED-PTSD appears requires further study.

Language: Английский

---

Naltrexone-Bupropion and Behavior Therapy, Alone and Combined, for Binge-Eating Disorder: Randomized Double-Blind Placebo-Controlled Trial

American Journal of Psychiatry, Journal Year: 2022, Volume and Issue: 179(12), P. 927 - 937

Published: Oct. 26, 2022

Binge-eating disorder, the most prevalent eating is a serious public health problem associated with obesity, psychiatric and medical comorbidities, functional impairments. disorder remains underrecognized infrequently treated, few evidence-based treatments exist. The authors tested effectiveness of naltrexone-bupropion behavioral weight loss therapy (BWL), alone combined, for binge-eating comorbid obesity.

Language: Английский

---

A framework for conceptualising early intervention for eating disorders

European Eating Disorders Review, Journal Year: 2022, Volume and Issue: 31(2), P. 320 - 334

Published: Nov. 25, 2022

Abstract Objective This paper outlines the evidence base for early intervention eating disorders; provides a global overview of how disorders is provided in different regions and settings; proposes policy, service, clinician research recommendations to progress disorders. Method Results Currently, access disorder treatment often takes many years or does not occur at all. despite neurobiological, clinical socioeconomic showing that may improve outcomes facilitate full sustained recovery from an disorder. There also considerable variation worldwide care provided, with marked inequalities provision. Despite these barriers, there are existing evidence‐based approaches being made scaling these. Conclusions We propose action steps field will transform service provision detection, everyone affected by disorders, regardless age, status personal characteristics.

Language: Английский

---

Toward a more comprehensive understanding and support of parents with a child experiencing an eating disorder

International Journal of Eating Disorders, Journal Year: 2023, Volume and Issue: 56(7), P. 1275 - 1285

Published: March 21, 2023

Abstract Objective The majority of eating disorder ( ED ) carer research has been conducted with parents adult patients, using qualitative methodologies, focusing on burden and distress during treatment. This article aimed to use results from a large, national, quantitative survey child or adolescent patients as springboard for encouraging more comprehensive investigation parent experiences. Methods online assessed treatment experiences DASS ‐21) but also less commonly investigated topics including symptom detection, primary care providers, impacts physical psychological health, romantic relationship, finances, employment. Results Key findings included N = 439; 91.6% female): were the first person notice symptoms in 81.8% cases; had only 14.7% chance helpful experience both general practitioner therapist they saw; needed see M 3.55 therapists before finding one that could help; reported worse than normal health (96.0%), (70.5%), relationship (92.7%); required 70.06 days leave work their (per household); 91.8% accessed private sector median out‐of‐pocket expenses AUD 10,0001–AUD 20,000. Discussion Recommendations address practice gaps include: increased focus supporting initial detection; improving experiences; and, increasing number providers. Urgently are solutions overwhelming demand services clearly, support parents. Such strategies vital reducing overall EDs. Public Significance Most (ED) caregiver focused used large national explore adolescent's areas, such care, impact employment finances. Findings suggested mixed providers very significant toll illness domains measured. provided how these important areas can be addressed.

Language: Английский

---

Naltrexone/bupropion for binge‐eating disorder: A randomized, double‐blind, placebo‐controlled trial

Obesity, Journal Year: 2023, Volume and Issue: 31(11), P. 2762 - 2773

Published: Sept. 26, 2023

Abstract Objective Binge‐eating disorder (BED) is a prevalent psychiatric associated with obesity. Few evidence‐based treatments exist for BED, particularly pharmacological options. This study tested the efficacy of naltrexone/bupropion BED. Methods A randomized, double‐blind, placebo‐controlled, 12‐week trial BED and without Eighty‐nine patients (70.8% women, 69.7% White, mean age 45.7 y, BMI 35.1 kg/m 2 , 77.5% ≥ 30 ) were randomized to placebo ( n = 46) or 43), randomization stratified by obesity status gender; 92.1% completed post‐treatment assessments. Results Mixed models binge‐eating frequency revealed significant reductions that did not differ significantly between placebo. Logistic regression remission rates significantly. Obesity predict, moderate, outcomes considered either continuously categorically. was greater percentage weight loss than had higher attaining ≥5% (27.9% vs. 6.5%). predict moderate weight‐loss outcomes. Conclusions Naltrexone/bupropion demonstrate effectiveness reducing binge eating relative but showed reduction in medication

Language: Английский

---

Direct economic burden of mental health disorders associated with polycystic ovary syndrome: Systematic review and meta-analysis

eLife, Journal Year: 2023, Volume and Issue: 12

Published: Aug. 3, 2023

Background: Polycystic ovary syndrome (PCOS) is the most common hormone disorder affecting about one in seven reproductive-aged women worldwide and approximately 6 million United States (U.S.). PCOS can be a significant burden to those affected associated with an increased prevalence of mental health (MH) disorders such as depression, anxiety, eating disorders, postpartum depression. We undertook this study determine excess economic MH order allow for more accurate prioritization public priority. Methods: Following PRISMA reporting guidelines systematic review, we searched PubMed, Web Science, EBSCO, Medline, Scopus, PsycINFO through July 16, 2021, studies on PCOS. Excluded were not humans, without controls, original data, or peer reviewed. As depression by far assessed studies, performed our meta-analysis these disorders. Meta-analyses using DerSimonian–Laird random effects model compute pooled estimates ratios (PRs) associations between then calculated direct costs related U.S. dollars (USD) suffering from alone. The quality selected was Newcastle-Ottawa Scale. Results: screened 78 articles title/abstract, 43 full text, included 25 articles. Pooled PRs 1.42 (95% confidence interval [CI]: 1.32–1.52) 1.65 CI: 1.44–1.89) 1.48 PR: 1.06–2.05) 1.20 0.96–1.50) relative controls. In U.S., additional healthcare estimated $1.939 billion/yr, $1.678 $0.644 billion/yr 2021 USD, respectively. Postpartum excluded cost analyses due non-significant result. Taken together, $4.261 USD. Conclusions: Overall, annual PCOS, namely exceeds $4 billion USD population together prior work, data suggest that healthcare-related $15 yearly, considering diagnosis, PCOS-associated MH, reproductive, vascular, metabolic has much same across world, attributable globally enormous, mandating scientific policy community increase its focus important disorder. Funding: supported, part, Challenge: National Ovary Syndrome Association Foundation Research Education Excellence

Language: Английский

---